Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical Inc (AMIX) is a pioneer in developing catheter-based neural sensing technologies for neurological disorders. This page provides centralized access to official company announcements, regulatory updates, and breakthrough developments in microchip-enabled medical diagnostics.
Investors and industry professionals will find timely updates on AMIX's R&D milestones, strategic partnerships, and preclinical progress with its proprietary neural signal detection platform. The curated news feed ensures accurate tracking of advancements in minimally invasive neural disorder treatments.
Key updates include regulatory submissions, research collaborations, technology validations, and intellectual property developments. All content is sourced directly from company filings and authorized communications to maintain compliance and reliability.
Bookmark this page for streamlined monitoring of AMIX's progress in redefining neurological diagnostics through its microchip-integrated catheter technology. Check back regularly for verified updates on this development-stage innovator's journey toward clinical impact.
Autonomix Medical (NASDAQ: AMIX) reported Q2 FY2025 financial results and clinical progress. The company's ongoing proof-of-concept trial for pancreatic cancer pain showed promising results, with 83% pain reduction and 100% of lead-in patient responders achieving zero opioid use at 4-6 weeks post-procedure. Trial enrollment reached 60%, with a 79% responder rate among first 15 patients. The company reported a net loss of $2.8 million for Q2, with cash position of $5.2 million as of September 30, 2024. R&D expenses increased to $1.2 million, primarily due to clinical trial costs. Autonomix expects to complete trial enrollment by end of 2024 and aims for potential FDA clearance in 1H 2027.
Autonomix Medical (NASDAQ: AMIX) reported positive results from its proof-of-concept clinical trial for pancreatic cancer pain treatment. The trial, with 60% enrollment completed (15 patients), showed a 79% responder rate among treated patients. Key findings at 7 days post-procedure include a mean 4.96 reduction in VAS pain scale scores (63% reduction), zero opioid use after 24 hours, and 66% improvement in overall health status. Femoral access patients showed significant improvement while brachial access patients showed no improvement. The trial will enroll a total of 20 patients, using the company's catheter-based microchip sensing technology for nerve detection and RF ablation.
Autonomix Medical (NASDAQ: AMIX) announced positive 4-6 week follow-up data from the first five lead-in patients in their ongoing proof-of-concept human clinical trial. The study evaluates the safety and effectiveness of their transvascular energy delivery system for ablating problematic nerves to reduce pain in pancreatic cancer patients. Dr. Robert Schwartz, Chief Medical Officer, discussed these results in a Virtual Investor 'What This Means' segment.
Autonomix Medical (NASDAQ: AMIX) reported positive preliminary results from its ongoing proof-of-concept human clinical trial evaluating nerve ablation technology for pancreatic cancer pain. The trial's initial 'lead-in' cohort showed significant pain reduction in responding patients, with VAS scores decreasing from 8.0 pre-procedure to 1.33 at 4-6 weeks post-procedure. Notably, all responding patients completely eliminated opioid use within 4-6 weeks. The trial revealed that patients treated with femoral access responded positively, while those with brachial access showed no improvement. The company's technology uses a catheter-based microchip sensing array with enhanced neural signal detection capability, followed by RF ablation for targeted nerve treatment.
Autonomix Medical (NASDAQ: AMIX) has announced its participation in a Virtual Investor 'What This Means' segment scheduled for October 30, 2024. During this virtual event, Dr. Robert Schwartz, the company's Chief Medical Officer, will present additional findings from the 4-6 week follow-up data of the first five 'lead-in' patients from their ongoing proof-of-concept human clinical trial. The company, which specializes in precision nerve-targeted treatments, will make the segment accessible through their platform.
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on advancing innovative technologies for diagnosing and treating nervous system diseases, has announced the release of a new CEO Corner segment on its website. The segment features Brad Hauser, CEO of Autonomix, discussing Pain Awareness Month and the company's efforts to address the significant unmet need in pancreatic cancer pain.
This CEO Corner segment, now available on the Autonomix website, highlights the company's commitment to addressing critical issues in pain management, particularly in the context of pancreatic cancer. The release of this segment demonstrates Autonomix's ongoing efforts to communicate its mission and progress to stakeholders and the public.
Autonomix Medical, Inc. (NASDAQ: AMIX), a company focused on advancing precision nerve-targeted treatments, has been selected for a featured podium presentation at the 2024 Octane Medical Innovation Forum in Irvine, California on October 8-9, 2024. The forum brings together industry experts, entrepreneurs, investors, and thought leaders to discuss the latest insights and trends in the medical industry.
Brad Hauser, CEO of Autonomix, will present on the company's minimally invasive nerve-sensing, ablation, and verification platform technology. This first-in-class technology uses a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with up to 3,000 times greater sensitivity than current technologies. The platform also includes proprietary radio frequency (RF) ablation technology for targeted nerve treatment, offering a precision-guided approach to addressing various conditions from chronic pain management to hypertension and cardiology.
Autonomix Medical (NASDAQ: AMIX) has announced promising 4-6 week preliminary results from its ongoing proof-of-concept human clinical trial for pancreatic cancer pain treatment. The trial, evaluating the safety and effectiveness of transvascular energy ablation of problematic nerves, showed significant pain reduction in responders:
- 60% of patients responded with a mean 83% reduction in pain (VAS scale: 8.0 to 1.33)
- 66% of responders reported a VAS pain score of 0 or 1
- 100% of responders experienced clinically meaningful pain relief
- Pain relief was observed as early as 1-day post-procedure
The company's proprietary technology uses a catheter-based microchip sensing array antenna to detect neural signals with high sensitivity, followed by precision-guided RF ablation. The trial is on track to complete enrollment by year-end 2024.
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on innovative technologies for diagnosing and treating nervous system diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York, NY.
Key points:
- CEO Brad Hauser will present at the conference
- Management will be available for one-on-one meetings with qualified investors
- A video webcast of the presentation will be accessible on-demand from September 9, 2024, at 7:00 AM ET
- The webcast will be available on the Company's website for 90 days following the event
This presentation offers an opportunity for investors to gain insights into Autonomix's innovative medical technologies and future prospects.
Autonomix Medical, Inc. (NASDAQ: AMIX) announced that its technology and interim clinical trial findings will be featured in a podium presentation at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress. The presentation, titled 'Rethinking pain management: transforming patient outcomes with precision mapping technology and celiac nerve RF ablation in end stage cancer', will be given by Dr. Askar Sabirov, the primary investigator for the company's ongoing proof-of-concept human clinical trial in pain associated with pancreatic cancer.
The presentation will take place on September 16th, 2024, as part of the 'Future AI Applications in Interventional Radiology' session. Autonomix CEO Brad Hauser emphasized the importance of engaging with the scientific community and aligning data release with their publication strategy to raise awareness for their innovative platform technology.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
